Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
Retrieved on:
Monday, October 4, 2021
Filgotinib, Medicines and Healthcare products Regulatory Agency, Review, Sandborn, TNF, PMDA, European Directive on Traditional Herbal Medicinal Products, Induction, Union, Health care, Methotrexate, Volume Ten, Safety, RA, EQ-5D, EMA, MHRA, Interview, European Medicines Agency, MTX, European, Adult, Work, Disease, Ulcerative colitis, Product, Inflammatory bowel disease, Tablet, Gilead, Inflammatory Bowel Diseases, Inflammation, Ministry of Health, Labour and Welfare, JAK1, Eisai, WPAI, IBQ, Gilead Sciences, Fibrosis, Mayo, MCS, Quality of life (healthcare), Week, Diagnosis, IBD, Galapagos NV, Patient, Disease-modifying antirheumatic drug, CHMP, European Union, Contraindication, Quality of life, Conditional sentence, Pharmaceutical industry, Medical device
In addition to the physical impact from flare ups, there is also a psychological impact associated with UC.
Key Points:
- In addition to the physical impact from flare ups, there is also a psychological impact associated with UC.
- The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu .
- Filgotinib in UC has been filed in the European Union, Great-Britain and Japan, and a global Phase 3 program is ongoing in Crohns Disease.
- Clinically meaningful improvements in health-related quality of life among patients with ulcerative colitis treated with filgotinib: post hoc analysis of the phase 2b/3 SELECTION study.